Neoadjuvant Systemic Therapy in Breast Cancer: Use and Trends in Radiotherapy Practice

Koulis, Theodora; Beecham, K.; Speers, Caroline; Tyldesley, Scott; David, Valeriu; Simmons, Christine; Olson, Robert

doi:10.3747/co.24.3558

Cited by 3 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the several advantages of NAC for patients, several studies have shown very low existing rates NAC use in North America, with overall use of 20.2% in the US according to the National Cancer Database [ 11 ], and only 5% in a national Canadian study [ 12 ]. Interestingly, the recent reports during the COVID-19 pandemic have shown a significant rise in the use of neoadjuvant systemic therapy, both chemotherapy and endocrine therapy, within North America [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic

et al. 2021

View full text Add to dashboard Cite

Practice and behaviour change in healthcare is complex, and requires a set of critical steps that would be needed to implement and sustain the change. Neoadjuvant chemotherapy for breast cancer is traditionally used for locally advanced disease and is primarily advantageous for surgical downstaging purposes. However, it does also offer patients with certain biologic subtypes such as the triple negative or Her2 positive breast cancers the opportunity to improve survival, even in early stage disease. During the height of the pandemic, an opportunity and motivation for the increased use of neoadjuvant therapy in breast cancer was identified. This paper describes the conditions that have supported this practice change at the provider and institutional levels. We also include our own institutional algorithm based on tumor biology and extent of disease that have guided our decisions on breast cancer management during the pandemic. Our processes can be adapted by other institutions and breast oncology practices in accordance with local conditions and resources, during and beyond the pandemic.

show abstract

Section: Introductionmentioning

confidence: 99%

Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic

et al. 2021

View full text Add to dashboard Cite

show abstract

Role of Elective Nodal Irradiation in Patients With ypN0 After Neoadjuvant Chemotherapy Followed by Breast-Conserving Surgery (KROG 16-16)

Cho

Park

Choi

et al. 2019

Clinical Breast Cancer

View full text Add to dashboard Cite

Omission of Axillary Lymph Node Dissection is Associated with Inferior Survival in Breast Cancer Patients with Residual N1 Nodal Disease Following Neoadjuvant Chemotherapy

et al. 2020

View full text Add to dashboard Cite

Neoadjuvant Systemic Therapy in Breast Cancer: Use and Trends in Radiotherapy Practice

Abstract: BackgroundThe use of neoadjuvant systemic therapy (nast) in the treatment of breast cancer is increasing, and the

Cited by 3 publications

References 30 publications

Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic

Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic

Role of Elective Nodal Irradiation in Patients With ypN0 After Neoadjuvant Chemotherapy Followed by Breast-Conserving Surgery (KROG 16-16)

Omission of Axillary Lymph Node Dissection is Associated with Inferior Survival in Breast Cancer Patients with Residual N1 Nodal Disease Following Neoadjuvant Chemotherapy

Contact Info

Product

Resources

About